167 related articles for article (PubMed ID: 29786108)
1. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
2. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
3. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
4. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
[TBL] [Abstract][Full Text] [Related]
5. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
6. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract][Full Text] [Related]
7. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
10. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
11. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
Ning G; Zhu Q; Kang W; Lee H; Maher L; Suh YS; Michaud M; Silva M; Kwon JY; Zhang C; Lee C
BMC Cancer; 2021 Aug; 21(1):923. PubMed ID: 34399705
[TBL] [Abstract][Full Text] [Related]
12. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2‑positive breast cancer.
Matsumoto A; Hayashida T; Takahashi M; Jinno H; Kitagawa Y
Mol Med Rep; 2018 Jul; 18(1):958-964. PubMed ID: 29845287
[TBL] [Abstract][Full Text] [Related]
14. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
15. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Shibata T; Kan H; Murakami Y; Ureshino H; Watari K; Kawahara A; Kage M; Hattori S; Ono M; Kuwano M
Mol Cancer Ther; 2013 May; 12(5):737-46. PubMed ID: 23445612
[TBL] [Abstract][Full Text] [Related]
16. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
De Silva N; Schulz L; Paterson A; Qain W; Secrier M; Godfrey E; Cheow H; O'Donovan M; Lao-Sirieix P; Jobanputra M; Hochhauser D; Fitzgerald R; Ford H
Br J Cancer; 2015 Nov; 113(9):1305-12. PubMed ID: 26484410
[TBL] [Abstract][Full Text] [Related]
17. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
18. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
19. JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells.
Ma L; Zhu W; Wang Q; Yang F; Qian J; Xu T; Wang S; Zhou J; Shu Y
Oncotarget; 2016 Nov; 7(44):71790-71801. PubMed ID: 27708243
[TBL] [Abstract][Full Text] [Related]
20. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
